Description

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide present in human plasma, saliva, and urine. Plasma concentrations average around 200 ng/mL at age 20 and decline significantly with age — a pattern that first drew researchers’ attention in the 1970s.

Research Profile

GHK-Cu’s research footprint spans over four decades. Dr. Loren Pickart’s original work identified its ability to stimulate collagen synthesis in fibroblast cultures. Subsequent studies expanded the scope — demonstrating influence on decorin, glycosaminoglycans, and multiple gene pathways involved in tissue remodeling. A 2014 gene expression study found GHK-Cu modulated 4,000+ human genes, resetting expression patterns toward a healthier baseline.

Key Research Areas

Collagen and elastin synthesis stimulation
Wound healing acceleration and scar remodeling
Anti-inflammatory signaling (TGF-beta modulation)
Stem cell attraction to injury sites
Antioxidant enzyme upregulation (SOD, catalase)

Specifications

Sequence	Gly-His-Lys:Cu²⁺
Molecular Weight	403.93 g/mol
Purity	≥99% (HPLC verified)
Form	Lyophilized powder (blue-purple)
Quantity	50mg per vial
Storage	-20°C / protect from light

Related Research Peptides

GHK-Cu bridges two research categories — often studied alongside BPC-157 for tissue repair and alongside Epithalon for anti-aging mechanisms. See our guides on peptides for healing and peptides for anti-aging.

Research Dosage Protocols

GHK-Cu research spans two distinct delivery routes with different concentration requirements. Injectable protocols in animal studies use doses in the 1–10mg/kg range subcutaneously, with skin and wound healing models showing consistent results at the lower end of that range. Topical formulations studied in dermatological research typically use concentrations between 0.1–1% by weight. For injectable research, a 50mg vial reconstituted in 2mL bacteriostatic water yields 25mg/mL. Researchers focused on systemic effects (lung, liver, wound healing) tend toward subcutaneous delivery; those studying skin specifically often use intradermal or topical application.

Frequently Asked Questions

What’s the key difference between topical and injectable GHK-Cu research?

Topical GHK-Cu research focuses primarily on skin — collagen density, fine line reduction, wound closure, and barrier function. These studies use high surface-area exposure but accept limited systemic distribution. Injectable research delivers GHK-Cu systemically, enabling studies on lung tissue repair, liver regeneration, neurological protection, and anti-inflammatory gene expression across multiple organ systems. The two routes aren’t interchangeable study designs — topical tells you about skin-level mechanisms, while subcutaneous injection is needed to assess systemic bioactivity. Most published GHK-Cu literature uses injectable delivery.

Is the copper component of GHK-Cu a safety concern in research?

Copper in GHK-Cu is chelated — meaning it’s bound to the peptide rather than existing as free ionic copper. Free ionic copper (Cu²⁺) is cytotoxic at elevated concentrations. Chelated copper in the GHK-Cu complex does not behave like free copper salts. Published safety profiles show no copper toxicity at research doses, and the total copper mass delivered at typical experimental concentrations is a fraction of dietary intake. Researchers should still note baseline copper status in animal models, as GHK-Cu’s mechanisms depend partly on copper’s role in collagen cross-linking enzymes (lysyl oxidase activity).

Why does GHK-Cu solution appear blue or purple?

The blue-purple color comes from the copper coordination complex itself. When the GHK tripeptide chelates copper ions, the resulting complex absorbs wavelengths in the orange-red spectrum, which makes the solution appear blue. This is normal and expected — it’s actually a visual confirmation that copper is properly chelated rather than free in solution. The intensity of color correlates roughly with concentration. A colorless GHK-Cu solution may indicate poor copper loading or degradation. For quality control, the characteristic color is a simple (though not conclusive) authenticity indicator.

How do I reconstitute GHK-Cu for research applications?

GHK-Cu is typically supplied in larger quantities than most peptides (50mg or 100mg vials) due to lower per-milligram cost. For injectable research, reconstitute with bacteriostatic water — 2mL per 50mg vial gives 25mg/mL. GHK-Cu dissolves readily and should turn the characteristic blue color. For topical research formulations, it’s often dissolved in a carrier serum or gel base rather than bacteriostatic water. Store refrigerated after reconstitution. The copper complex is moderately stable — expect a 4–6 week working window at 2–8°C in sealed vials.

How do natural GHK-Cu levels change with age?

Plasma GHK concentrations decline significantly with age. Research indicates levels around 200ng/mL at age 20 drop to roughly 80ng/mL by age 60 — a reduction of more than 50% over four decades. This decline coincides with reduced collagen synthesis, slower wound healing, and decreased expression of genes involved in tissue repair. Dr. Loren Pickart’s foundational research identified this age-related depletion as relevant to GHK-Cu’s therapeutic research potential. The correlation doesn’t establish causation, but it frames the rationale behind longevity and skin aging research applications.

What’s the difference between GHK (the tripeptide) and GHK-Cu (the copper complex)?

GHK is the raw tripeptide: Glycine-Histidine-Lysine. It naturally chelates copper in biological tissue. GHK-Cu is the pre-formed complex with copper already bound. Research uses GHK-Cu rather than GHK alone because the copper-loaded form is the biologically active species — most of GHK’s documented effects (collagen stimulation, antioxidant gene activation, wound healing) require the copper-complexed form. Free GHK without copper is far less active. When researchers reference “copper peptide” in dermatological literature, they mean GHK-Cu specifically, not the uncomplexed tripeptide.

Has GHK-Cu been studied in combination with microneedling protocols?

Yes — microneedling creates transient microchannels in the stratum corneum that dramatically increase topical peptide penetration. Several dermatological studies have examined GHK-Cu as a post-microneedling topical application, with the rationale that enhanced dermal delivery amplifies the peptide’s collagen-stimulating effects beyond what either intervention achieves alone. Research using Franz diffusion cell models shows a 40–60x increase in GHK-Cu penetration following microneedling versus intact skin. This combination approach appears in both academic dermatology literature and aesthetic medicine research.

For research and laboratory use only. Not for human consumption. All peptides are sold strictly as research chemicals.

GHK-Cu